Findings

What do systematic reviews say?

124 questions · 124 findings · 18 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 16 · 12.9%GRADE not reported 22 · 17.7%Very low 31 · 25%Low 28 · 22.6%Moderate 12 · 9.7%High 15 · 12.1%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- FAE vs placebo · PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis))
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 418 participants
  Low
Direct match · question page
- FAE vs MTX · PASI 75
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  RR 0.8 [0.28, 2.29]
  1 study · 51 participants
  Very low
Direct match · question page
- FAE vs placebo · PASI 50
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  RR 4.55 [2.8, 7.4]
  2 studies · 247 participants
  Low
Direct match · question page
- FAE vs MTX · PASI 50
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  RR 0.71 [0.41, 1.22]
  1 study · 51 participants
  Very low
Direct match · question page
- FAE vs placebo · Quality of life (QoL)
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 175 participants
  Low

FAE vs placebo

PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 418 participants
Low

FAE vs MTX

Quality of life (QoL) ‐ not measured · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FAE vs MTX

Common nuisance AEs (not leading to treatment discontinuation) · psoriasis

It is very uncertain whether FAE changes common nuisance AEs (not leading to treatment discontinuation) compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.89 [0.77, 1.03]
1 study · 54 participants
Very low

FAE vs MTX

PASI 50 · psoriasis

It is very uncertain whether FAE changes PASI 50 compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.71 [0.41, 1.22]
1 study · 51 participants
Very low

FAE vs MTX

Percentage of participants reaching PASI 75 · psoriasis

It is very uncertain whether FAE changes PASI 75 compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.8 [0.28, 2.29]
1 study · 51 participants
Very low

FAE vs MTX

PASI 90 · psoriasis

It is very uncertain whether FAE changes PASI 90 compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.48 [0.05, 4.98]
1 study · 51 participants
Very low

FAE vs placebo

Withdrawals due to adverse events · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

FAE vs placebo

QoL · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 175 participants
Low

FAE vs placebo

Common nuisance AEs (not leading to treatment discontinuation) · psoriasis

FAE probably leads to higher common nuisance AEs (not leading to treatment discontinuation) compared with placebo (moderate certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 4.72 [2.45, 9.08]
1 study · 99 participants
Moderate

FAE vs placebo

PASI 50 · psoriasis

FAE may leads to higher PASI 50 compared with placebo (low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 4.55 [2.8, 7.4]
2 studies · 247 participants
Low

FAE vs placebo

Percentage of participants reaching PASI 75 · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 247 participants
Low

FAE vs placebo

PASI 90 ‐ not measured · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FAE vs MTX

PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Very low

FAE vs MTX

Withdrawals due to adverse events · psoriasis

It is very uncertain whether FAE changes AEs leading to treatment discontinuation compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.19 [0.02, 1.53]
1 study · 51 participants
Very low

Antenatal pelvic floor muscle training vs control

Faecal incontinence in late pregnancy · pregnant women who were incontinent when randomised

1 finding from 1 review

Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal… 2020 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Antenatal pelvic floor muscle training vs control

Faecal incontinence mid‐postnatal period (> 3‐6 months) · pregnant women who were incontinent when randomised

1 finding from 1 review

Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal… 2020 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Antenatal pelvic floor muscle training vs control

Faecal incontinence late postnatal period (> 6‐12 months) · pregnant women who were incontinent when randomised

1 finding from 1 review

Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal… 2020 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Antenatal pelvic floor muscle training vs control

Faecal incontinence‐specific quality of life · pregnant women who were incontinent when randomised

1 finding from 1 review

Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal… 2020 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Antenatal pelvic floor muscle training vs control

Faecal incontinence in late pregnancy · pregnant women, some of who were incontinent symptoms and some who were not when randomised

Antenatal pelvic floor muscle training showed no clear difference in faecal incontinence in late pregnancy compared with control (moderate certainty).

1 finding from 1 review

Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal… 2020 · Cochrane Headline outcomes only
RR 0.64 [0.36, 1.14]
3 studies · 910 participants
Moderate

Antenatal pelvic floor muscle training vs control

Faecal incontinence mid‐postnatal period (> 3‐6 months) · pregnant women, some of who were incontinent symptoms and some who were not when randomised

1 finding from 1 review

Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal… 2020 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported